Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen	CYP2E1 COQ6	6.55e-04	40	19	2	GO:0016709
GeneOntologyMolecularFunction	hydrolase activity, hydrolyzing O-glycosyl compounds	MAN2B2 NAGLU	4.26e-03	103	19	2	GO:0004553
GeneOntologyMolecularFunction	monooxygenase activity	CYP2E1 COQ6	5.27e-03	115	19	2	GO:0004497
GeneOntologyMolecularFunction	endopeptidase activity	ATG4D ADAMTS13 PCSK9	7.44e-03	430	19	3	GO:0004175
GeneOntologyMolecularFunction	hydrolase activity, acting on glycosyl bonds	MAN2B2 NAGLU	8.15e-03	144	19	2	GO:0016798
GeneOntologyCellularComponent	endoplasmic reticulum lumen	ACHE ADAMTS13 PCSK9	2.71e-03	332	18	3	GO:0005788
GeneOntologyCellularComponent	lysosomal lumen	MAN2B2 NAGLU	3.17e-03	98	18	2	GO:0043202
Domain	BAH	TNRC18 BAHCC1	5.36e-05	11	19	2	SM00439
Domain	BAH	TNRC18 BAHCC1	5.36e-05	11	19	2	PF01426
Domain	BAH_dom	TNRC18 BAHCC1	5.36e-05	11	19	2	IPR001025
Domain	BAH	TNRC18 BAHCC1	5.36e-05	11	19	2	PS51038
Domain	I-set	MAG LINGO4	1.57e-02	190	19	2	PF07679
Domain	Ig_I-set	MAG LINGO4	1.57e-02	190	19	2	IPR013098
Domain	Ig_sub2	MAG LINGO4	2.34e-02	235	19	2	IPR003598
Domain	IGc2	MAG LINGO4	2.34e-02	235	19	2	SM00408
Domain	Leu-rich_rpt	LINGO4 NLRX1	3.05e-02	271	19	2	IPR001611
Pubmed	The Transcription Factors EBF1 and EBF2 Are Positive Regulators of Myelination in Schwann Cells.	MAG AJAP1	3.83e-05	17	19	2	27889898
Pubmed	Evaluation of candidate genes for cholinesterase activity in farmworkers exposed to organophosphorus pesticides: association of single nucleotide polymorphisms in BCHE.	CYP2E1 ACHE	1.22e-04	30	19	2	20529763
Interaction	FSTL4 interactions	PCSK9 MAN2B2 NAGLU	4.17e-06	34	19	3	int:FSTL4
Interaction	CRISP2 interactions	PCSK9 MAN2B2 NAGLU	6.87e-06	40	19	3	int:CRISP2
Interaction	TRGV3 interactions	PCSK9 MAN2B2 NAGLU	1.81e-05	55	19	3	int:TRGV3
Interaction	PI15 interactions	PCSK9 MAN2B2 NAGLU	6.22e-05	83	19	3	int:PI15
Interaction	C1QB interactions	PCSK9 MAN2B2 NAGLU	9.02e-05	94	19	3	int:C1QB
Interaction	EDN3 interactions	PCSK9 MAN2B2 NAGLU	1.36e-04	108	19	3	int:EDN3
Interaction	LYZL1 interactions	PCSK9 MAN2B2 NAGLU	1.77e-04	118	19	3	int:LYZL1
Interaction	IDS interactions	PCSK9 MAN2B2 NAGLU	1.86e-04	120	19	3	int:IDS
Interaction	NCR3 interactions	PCSK9 MAN2B2 NAGLU	1.86e-04	120	19	3	int:NCR3
Interaction	LYPD4 interactions	PCSK9 MAN2B2 NAGLU	2.00e-04	123	19	3	int:LYPD4
Interaction	ALPP interactions	PCSK9 MAN2B2 NAGLU	2.00e-04	123	19	3	int:ALPP
Interaction	IL5RA interactions	PCSK9 MAN2B2 NAGLU	2.05e-04	124	19	3	int:IL5RA
Interaction	CBLN4 interactions	PCSK9 MAN2B2 NAGLU	2.20e-04	127	19	3	int:CBLN4
Interaction	TGIF2LX interactions	TNRC18 BAHCC1	5.20e-04	36	19	2	int:TGIF2LX
Interaction	TMEM87A interactions	PCSK9 MAN2B2 NAGLU	6.83e-04	187	19	3	int:TMEM87A
Interaction	KLK2 interactions	PCSK9 MAN2B2	7.09e-04	42	19	2	int:KLK2
Interaction	FCGR3B interactions	PCSK9 MAN2B2	7.43e-04	43	19	2	int:FCGR3B
Interaction	COL4A1 interactions	MAG ACHE	9.26e-04	48	19	2	int:COL4A1
Interaction	PRG3 interactions	PCSK9 NAGLU	9.64e-04	49	19	2	int:PRG3
Interaction	DPEP2 interactions	PCSK9 MAN2B2	9.64e-04	49	19	2	int:DPEP2
Interaction	LY86 interactions	PCSK9 MAN2B2 NAGLU	1.05e-03	217	19	3	int:LY86
Interaction	SCGB2A2 interactions	HEMK1 COQ6 NAGLU	1.14e-03	223	19	3	int:SCGB2A2
Interaction	CLGN interactions	PCSK9 MAN2B2 NAGLU	1.32e-03	235	19	3	int:CLGN
Interaction	NXPH3 interactions	PCSK9 MAN2B2	1.35e-03	58	19	2	int:NXPH3
Interaction	GGH interactions	PCSK9 MAN2B2 NAGLU	1.45e-03	243	19	3	int:GGH
GeneFamily	Blood group antigens\|CD molecules\|I-set domain containing\|Immunoglobulin like domain containing	MAG LINGO4	5.76e-03	161	13	2	593
ToppCell	10x5'-bone_marrow-Lymphocytic_Invariant-Inducer-like-ILC3\|bone_marrow / Manually curated celltypes from each tissue	CYP2E1 LINGO4 ADAMTS13	3.73e-05	155	19	3	83430a64c2cb5ad29caa3dacba76c28dd204ac40
ToppCell	Fetal_29-31_weeks-Immune-mast_cell-D062\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	CYP2E1 LINGO4 AJAP1	3.95e-05	158	19	3	0c27c475289c70b17b6a66fc71f628511c5f0ae1
ToppCell	facs-Trachea-3m-Mesenchymal-myofibroblast-tracheobronchial_smooth_muscle_cell-smooth_muscle_cell_of_trachea_l32-30\|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	MAG ACHE AJAP1	4.41e-05	164	19	3	3caf4cdaa0164907893fea61e251fd8b5fa926e4
ToppCell	368C-Myeloid-Macrophage-FABP4+_Macrophage_2\|Myeloid / Donor, Lineage, Cell class and subclass (all cells)	SCNN1D MAN2B2 NAGLU	5.00e-05	171	19	3	e59afa0a773dca3b9c208d17510ea55703b42598
ToppCell	COVID-19_Mild-Neu_2\|COVID-19_Mild / 5 Neutrophil clusters in COVID-19 patients	RPUSD4 HEMK1 NLRX1	5.09e-05	172	19	3	f5fd08b42c002d4693646b27e7b708eceb49524f
ToppCell	5'-Adult-LymphNode-Hematopoietic-T_cells-ILC3\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	MAG CYP2E1 LINGO4	6.31e-05	185	19	3	7d6954bb04368ec62b284ba6c3021a15fbdfdee6
Drug	bromophos	CYP2E1 ACHE COQ6	4.73e-07	19	19	3	CID000016422
Drug	OOS-TMP	CYP2E1 ACHE COQ6	5.57e-07	20	19	3	CID000009039
Drug	disulfoton	ACHE COQ6 NAGLU	8.63e-07	23	19	3	CID000003118
Drug	4-methylumbelliferone	CYP2E1 MAN2B2 COQ6 NAGLU	3.91e-06	132	19	4	CID003364573
Drug	dimethyl mercury	CYP2E1 ACHE	3.95e-06	4	19	2	ctd:C073972
Drug	diazoxon	MAG CYP2E1 ACHE	4.08e-06	38	19	3	CID000013754
Drug	propetamphos	CYP2E1 ACHE	6.59e-06	5	19	2	ctd:C035967
Drug	1,2-epoxy-4-vinylcyclohexane	CYP2E1 ACHE	6.59e-06	5	19	2	ctd:C118009
Drug	2,5-dichlorophenol	CYP2E1 COQ6	9.88e-06	6	19	2	CID000000066
Drug	HJ4	MAN2B2 NAGLU	1.38e-05	7	19	2	CID005493402
Drug	dibutylnitrosamine	CYP2E1 ACHE	1.38e-05	7	19	2	ctd:C012279
Drug	Ergocryptine-alpha [511-09-1]; Up 200; 7uM; PC3; HT_HG-U133A	MAG CYP2E1 HEMK1 ADAMTS13	1.79e-05	194	19	4	4552_UP
Drug	4-vinylcyclohexene	CYP2E1 ACHE	1.84e-05	8	19	2	ctd:C013733
Drug	coumarin 3,4-epoxide	CYP2E1 COQ6	1.84e-05	8	19	2	CID000126771
Drug	Chlorogenic acid [327-97-9]; Down 200; 11.2uM; MCF7; HT_HG-U133A	CYP2E1 NLRX1 BAHCC1 AJAP1	1.90e-05	197	19	4	4142_DN
Drug	Flucloxacillin sodium [1847-24-1]; Up 200; 8.4uM; PC3; HT_HG-U133A	CYP2E1 HEMK1 BAHCC1 NAGLU	1.94e-05	198	19	4	5102_UP
Drug	piperonyl butoxide	CYP2E1 ACHE COQ6	2.28e-05	67	19	3	CID000005794
Drug	methoxyresorufin	CYP2E1 COQ6 NAGLU	2.49e-05	69	19	3	CID000119220
Drug	alachlor	CYP2E1 ACHE COQ6	2.72e-05	71	19	3	CID000002078
Drug	sulconazole	CYP2E1 COQ6	2.96e-05	10	19	2	CID000005318
Drug	acephate	CYP2E1 ACHE	2.96e-05	10	19	2	ctd:C001969
Drug	styrene	MAG CYP2E1 COQ6	3.60e-05	78	19	3	CID000007501
Drug	phenthoate	CYP2E1 ACHE	3.61e-05	11	19	2	ctd:C008838
Drug	1,4-dichlorobut-2-ene	CYP2E1 COQ6	4.33e-05	12	19	2	CID000015122
Drug	pentoxyresorufin	CYP2E1 COQ6 NAGLU	5.00e-05	87	19	3	CID000107683
Drug	angelicin	CYP2E1 ACHE	5.12e-05	13	19	2	ctd:C011659
Drug	2-chloro-1,1-difluoroethene	CYP2E1 COQ6	5.12e-05	13	19	2	CID000009664
Drug	AC1MHDWA	ACHE COQ6	5.97e-05	14	19	2	CID003001665
Drug	dihydrosafrole	CYP2E1 COQ6	6.88e-05	15	19	2	CID000007197
Drug	Ficusin	CYP2E1 ACHE	6.88e-05	15	19	2	ctd:D005363
Drug	asoxime chloride	CYP2E1 ACHE	6.88e-05	15	19	2	ctd:C022870
Drug	propafenone	CYP2E1 SCNN1D COQ6	7.13e-05	98	19	3	CID000004932
Drug	4-nitropyrene	CYP2E1 COQ6	7.86e-05	16	19	2	CID000062134
Drug	HCFC-141b	CYP2E1 COQ6	7.86e-05	16	19	2	CID000015586
Drug	CAS 76963-41-2	ACHE COQ6	7.86e-05	16	19	2	CID000004513
Drug	Chlorpromazine	MAG CYP2E1 ACHE HEMK1 MAN2B2	7.99e-05	564	19	5	ctd:D002746
Drug	propazine	CYP2E1 COQ6	8.91e-05	17	19	2	CID000004937
Drug	lonazolac	CYP2E1 COQ6	8.91e-05	17	19	2	CID000068706
Drug	schizandrol B	CYP2E1 ACHE	8.91e-05	17	19	2	ctd:C033585
Drug	cyclooctane	ACHE COQ6	8.91e-05	17	19	2	CID000009266
Drug	styrene glycol	CYP2E1 COQ6	1.00e-04	18	19	2	CID000007149
Drug	A0006	CYP2E1 ACHE	1.00e-04	18	19	2	CID000007863
Drug	DETA	MAG CYP2E1 ACHE	1.12e-04	114	19	3	CID000004284
Drug	6\|A-Hydroxycortisol	CYP2E1 COQ6	1.12e-04	19	19	2	CID000150985
Drug	3,4-PCB	CYP2E1 COQ6	1.24e-04	20	19	2	CID000018102
Drug	HI-6 chloride	CYP2E1 ACHE	1.24e-04	20	19	2	CID005484128
Drug	carbohydrazide	CYP2E1 COQ6	1.24e-04	20	19	2	CID000073948
Drug	dichloromethyl	CYP2E1 COQ6	1.24e-04	20	19	2	CID000123193
Drug	dichlobenil	CYP2E1 COQ6	1.37e-04	21	19	2	CID000003031
Drug	naphthalene	CYP2E1 COQ6 NAGLU	1.40e-04	123	19	3	CID000000931
Drug	2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide	CYP2E1 SCNN1D ACHE COQ6	1.52e-04	336	19	4	ctd:C511621
Drug	crocin	CYP2E1 ACHE	1.65e-04	23	19	2	ctd:C029036
Drug	HCFC-123	CYP2E1 COQ6	1.65e-04	23	19	2	CID000009385
Drug	hyperoside	CYP2E1 ACHE	1.80e-04	24	19	2	ctd:C021304
Drug	coumarin	CYP2E1 ACHE COQ6	2.01e-04	139	19	3	CID000000323
Drug	CMP-Neu5Ac	MAG SCNN1D NAGLU	2.09e-04	141	19	3	CID000000316
Drug	AC1L40XN	CYP2E1 COQ6	2.12e-04	26	19	2	CID000099490
Drug	Aspartame	CYP2E1 ACHE	2.12e-04	26	19	2	ctd:D001218
Drug	AC1L1MOZ	SCNN1D NAGLU	2.29e-04	27	19	2	CID000031958
Drug	p-nitrophenyl	ACHE MAN2B2 NAGLU	2.32e-04	146	19	3	CID000007416
Drug	IBMP	CYP2E1 COQ6	2.46e-04	28	19	2	CID000032594
Drug	N-nitrosodibutylamine	CYP2E1 ACHE	2.46e-04	28	19	2	CID000013542
Drug	cyfluthrin	CYP2E1 ACHE	2.64e-04	29	19	2	ctd:C052570
Drug	Fenitrothion	CYP2E1 ACHE	2.64e-04	29	19	2	ctd:D005278
Drug	4-hydroxyantipyrine	CYP2E1 COQ6	2.64e-04	29	19	2	CID000098889
Drug	NSC-258597	CYP2E1 ACHE	2.64e-04	29	19	2	CID000318796
Drug	PB-5	CYP2E1 COQ6	2.83e-04	30	19	2	CID005289111
Drug	dioxolane	CYP2E1 COQ6	2.83e-04	30	19	2	CID000012586
Drug	lemongrass oil	MAG CYP2E1	3.02e-04	31	19	2	ctd:C052901
Drug	paraoxon	CYP2E1 ACHE COQ6	3.27e-04	164	19	3	CID000009395
Drug	GTS-21	CYP2E1 ACHE	3.64e-04	34	19	2	CID005310985
Drug	cis,trans-1,2-dichloroethylene	CYP2E1 COQ6	3.86e-04	35	19	2	CID000010900
Drug	toluene	CYP2E1 SCNN1D COQ6	3.95e-04	175	19	3	CID000001140
Drug	4-nitrophenol	CYP2E1 COQ6 NAGLU	4.08e-04	177	19	3	CID000000980
Drug	profenofos	CYP2E1 ACHE	4.09e-04	36	19	2	ctd:C024273
Drug	hexamethylphosphoramide	CYP2E1 COQ6	4.09e-04	36	19	2	CID000012679
Drug	Monocrotophos	CYP2E1 ACHE	4.32e-04	37	19	2	ctd:D008999
Drug	Helveticoside [630-64-8]; Down 200; 7.4uM; PC3; HT_HG-U133A	HEMK1 NLRX1 BAHCC1	4.65e-04	185	19	3	4327_DN
Drug	acetone	MAG CYP2E1 COQ6	4.80e-04	187	19	3	CID000000180
Drug	ethanol	MAG CYP2E1 SCNN1D ACHE COQ6	5.02e-04	837	19	5	CID000000702
Drug	procainamide	CYP2E1 SCNN1D ACHE	5.02e-04	190	19	3	CID000004913
Drug	pyridine-2-aldoxime	MAG ACHE	5.05e-04	40	19	2	CID005356792
Drug	sodium bisulfide	ACHE NAGLU	5.05e-04	40	19	2	ctd:C025451
Drug	alprazolam	CYP2E1 ACHE COQ6	5.26e-04	193	19	3	CID000002118
Drug	Bephenium hydroxynaphthoate [3818-50-6]; Down 200; 9uM; MCF7; HT_HG-U133A	CYP2E1 NLRX1 BAHCC1	5.26e-04	193	19	3	5628_DN
Drug	lauric acid	CYP2E1 SCNN1D COQ6	5.26e-04	193	19	3	CID000003893
Drug	SC 19220; Up 200; 10uM; PC3; HT_HG-U133A	CYP2E1 HEMK1 COQ6	5.34e-04	194	19	3	7065_UP
Drug	Indomethacin [53-86-1]; Up 200; 11.2uM; MCF7; HT_HG-U133A	HEMK1 NLRX1 BAHCC1	5.50e-04	196	19	3	7409_UP
Drug	Fillalbin [4540-25-4]; Down 200; 13.8uM; MCF7; HT_HG-U133A	HEMK1 ADAMTS13 NLRX1	5.50e-04	196	19	3	4172_DN
Drug	Sulfadimethoxine [122-11-2]; Up 200; 12.8uM; PC3; HT_HG-U133A	MAG HEMK1 BAHCC1	5.50e-04	196	19	3	7400_UP
Drug	N-acetylhexosamine	ACHE PCSK9 MAN2B2 NAGLU	5.52e-04	472	19	4	CID000000899
Drug	m-xylene	CYP2E1 COQ6	5.57e-04	42	19	2	CID000007929
Drug	Menadione [58-27-5]; Down 200; 23.2uM; HL60; HT_HG-U133A	HEMK1 NLRX1 BAHCC1	5.58e-04	197	19	3	2439_DN
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A	HEMK1 BAHCC1 NAGLU	5.58e-04	197	19	3	3566_DN
Drug	Captopril [62571-86-2]; Up 200; 17.2uM; MCF7; HT_HG-U133A	HEMK1 ADAMTS13 AJAP1	5.66e-04	198	19	3	4410_UP
Drug	Oxprenolol hydrochloride [6452-73-9]; Up 200; 13.2uM; HL60; HT_HG-U133A	HEMK1 ADAMTS13 AJAP1	5.66e-04	198	19	3	6145_UP
Drug	Flunixin meglumine [42461-84-7]; Up 200; 8.2uM; MCF7; HT_HG-U133A	CYP2E1 BAHCC1 AJAP1	5.75e-04	199	19	3	4735_UP
Drug	Meropenem [96036-03-2]; Down 200; 10.4uM; MCF7; HT_HG-U133A	HEMK1 BAHCC1 AJAP1	5.75e-04	199	19	3	3564_DN
Drug	Nalidixic acid sodium salt hydrate; Up 200; 14.6uM; PC3; HT_HG-U133A	SCNN1D NLRX1 NAGLU	5.75e-04	199	19	3	7367_UP
Drug	Myosmine [532-12-7]; Up 200; 27.4uM; MCF7; HT_HG-U133A	CYP2E1 BAHCC1 AJAP1	5.83e-04	200	19	3	4759_UP
Disease	fibroblast growth factor 23 measurement	ADAMTS13 PCSK9	3.49e-04	43	19	2	EFO_0009381
Disease	systolic blood pressure change measurement	KRBA1 NAGLU	4.17e-04	47	19	2	EFO_0006944
Disease	multiple sclerosis (is_marker_for)	MAG ACHE	4.54e-04	49	19	2	DOID:2377 (is_marker_for)
Disease	non-alcoholic fatty liver disease (biomarker_via_orthology)	CYP2E1 ADAMTS13	7.98e-04	65	19	2	DOID:0080208 (biomarker_via_orthology)
Disease	type 1 diabetes mellitus (is_marker_for)	CYP2E1 ACHE	9.77e-04	72	19	2	DOID:9744 (is_marker_for)
Disease	Drug toxicity	CYP2E1 ACHE	1.33e-03	84	19	2	C0013221
Disease	Adverse reaction to drug	CYP2E1 ACHE	1.33e-03	84	19	2	C0041755
Disease	Parkinson Disease	MAG CYP2E1	1.36e-03	85	19	2	C0030567

Protein segments in the cluster

Peptide	Gene	Start	Entry
MSLWGSWGSRPPSPA	nan	281	Q6ZR03
STLSWPLWMGVPHGY	ACHE	466	P22303
WLPRTRSPSLWMGGH	BAHCC1	821	Q9P281
SMSIRWPGRPLGSHA	AJAP1	11	Q9UKB5
PHSGPLVSWRRWSGA	COQ6	16	Q9Y2Z9
AAVHGRWSSWGPRSP	ADAMTS13	381	Q76LX8
WGRMGNLHTWDGPLP	NAGLU	201	P54802
SMWRQVHSSWNLPPG	CYP2E1	21	P05181
MGSDAWVGLWRPHRP	ODF3B	1	A8MYP8
ASWMWTLPRGPRWAH	KRBA1	851	A5PL33
ASRGGHWGAWMPSSI	MAG	16	P20916
SERSWTHLPWGPMDL	HEMK1	221	Q9Y5R4
MGTVSSRRSWWPLPL	PCSK9	1	Q8NBP7
GMLPNKTPRGSWRWS	FAM205A	1086	Q6ZU69
MRWGHHLPRASWGSG	NLRX1	1	Q86UT6
WMGTWRPHRPRGPIM	ODF3	6	Q96PU9
GPRPHSVWGSSRWLR	QRFP	46	P83859
LSMLHRWSWRTGPGR	MAN2B2	961	Q9Y2E5
LWPGHLSGPRRLTWS	SCNN1D	16	P51172
PAPTVSWMRPHGAWL	LINGO4	441	Q6UY18
SWMRPHGAWLGRAGR	LINGO4	446	Q6UY18
MAAPRWSASGPWIRG	RPUSD4	1	Q96CM3
SRYHGPARWMPPRWA	ATG4D	186	Q86TL0
THPWLPRSGNASMWL	TNRC18	801	O15417